1. Home
  2. INNV vs ATAI Comparison

INNV vs ATAI Comparison

Compare INNV & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InnovAge Holding Corp.

INNV

InnovAge Holding Corp.

HOLD

Current Price

$8.07

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

ATAI

ATAI Life Sciences N.V.

HOLD

Current Price

$4.12

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INNV
ATAI
Founded
2007
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
INNV
ATAI
Price
$8.07
$4.12
Analyst Decision
Sell
Strong Buy
Analyst Count
1
8
Target Price
$7.00
$15.88
AVG Volume (30 Days)
216.1K
6.6M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.14
N/A
Revenue
$853,699,000.00
$4,089,000.00
Revenue This Year
$12.85
N/A
Revenue Next Year
$8.88
N/A
P/E Ratio
$58.86
N/A
Revenue Growth
11.76
1227.60
52 Week Low
$2.84
$1.29
52 Week High
$10.69
$6.73

Technical Indicators

Market Signals
Indicator
INNV
ATAI
Relative Strength Index (RSI) 50.12 50.13
Support Level $7.57 $4.05
Resistance Level $8.63 $4.30
Average True Range (ATR) 0.33 0.34
MACD 0.02 -0.00
Stochastic Oscillator 50.89 28.28

Price Performance

Historical Comparison
INNV
ATAI

About INNV InnovAge Holding Corp.

InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.

About ATAI ATAI Life Sciences N.V.

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Share on Social Networks: